Why did Alaunos (TCRT) stock go up? A Velaris merger and $350M PIPE

What happened

Alaunos Therapeutics closed Tuesday at $3.03, up about 189% from Monday’s $1.05. About 257 million shares traded, against roughly 3.8 million shares, fully diluted, before the deal. It had already risen 34% on Monday, on 3.4 million shares, with no filing that day.

The likely catalyst

Before the open, Alaunos said it had completed its acquisition of Velaris Therapeutics and agreed a private placement of about $350 million. Press release, 8-K.

What Velaris is. A private biotech in Waltham, Massachusetts, working on pulmonary arterial hypertension. Its lead program, VLR199, is designed to work the same way as Merck’s approved drug Winrevair. Two more, VLR247 and VLR258, are versions meant to spare two proteins linked to blood-related side effects, and VLR360 is an antibody against PDGF-B. None has been tested in people. The company expects first trial filings in 2027 and early data on VLR199 in 2028. Its programs come from Paragon Laboratories, which Fairmount founded. Presentation.

The deal. Velaris holders received 105,286 shares of Series B and 33,054 shares of Series C non-voting convertible preferred, each convertible into 1,000 common shares. The merger agreement valued Velaris at $200 million and Alaunos at $15 million plus its net cash.

The placement. Investors agreed to purchase 687,789 common shares at $1.4357 and 243,063 Series C shares at $1,435.70, about $350 million in all. Fairmount Healthcare Fund II leads, and Fairmount funds are putting in about $100 million. Closing was expected on 14 October; we found no 8-K confirming it by our cut-off. See PIPE financing.

The charter filing (item 5.03). It creates the two preferred series. The name change to Velaris Therapeutics, a reverse split and the increase in authorized shares are proposals for a future vote, not done.

Who runs it

Holger Weis remains chief executive officer and chairman. Michael Henderson, MD, is president of Velaris. Peter Harwin, a founding partner of Fairmount, joined the board on 13 October. Directors Robert Postma, Michael Jerman and Jaime Vieser have resigned, effective only on approval of the conversion. Fairmount then names three directors, giving Harwin and its picks four of five seats.

Money and dilution check

At 30 June, Alaunos had $124,000 of cash, $652,000 of stockholders’ equity and 50 million authorized common shares. 10-Q. It raised about $915,000 net at $1.46 in September. 8-K. Nasdaq has told it the shares face delisting over equity, and it has asked for a hearing. 8-K. The company says the placement funds it into 2029.

On the company’s table, the as-converted count is 386.9 million: about 1% legacy holders, 36% Velaris holders and 63% placement investors. The press release says 358.59 million; the filings don’t reconcile the two. Paragon’s two warrants, assumed Velaris options and a new equity plan come on top.

What if the vote fails?

Shares issued in the deal can’t vote on conversion. Insiders and the legacy preferred holders have agreed to vote for it, and the quorum was cut to one-third in September. 8-K. Alaunos must keep calling a meeting every six months until it passes.

From 13 April 2027, without approval, holders can require cash at the shares’ market value instead. The preferred converts into about 381.4 million shares: about $1.16 billion at $3.03, or $548 million at the $1.4357 deal price, against about $350 million raised. Series C terms.

How we measured: regular-session close to close, from Alpaca Markets (SIP) daily bars, split-adjusted. Volume is compared with the average of the 30 trading sessions before the move, which includes two heavy days on 17 and 18 September.